From: The effects of antipsychotic medications on microbiome and weight gain in children and adolescents
Cohort description | Mean age (years) | % Males | Drug(s) | Microbial taxonomy alterations | Microbial diversity alterations | Host metabolic alteration | Country | References |
---|---|---|---|---|---|---|---|---|
Adolescents (5 commencing treatment vs. 10 healthy controls) | 11.7 | 100 | Risperidone | Bacteroidetes: Firmicutes ratio↓ | Diversity ↑ | Higher BMI | USA | [96] |
Adolescents (18 treated over a year vs. 10 healthy controls) | 12.2 | 100 | Risperidone | Bacteroidetes: Firmicutes ratio↓, Proteobacteria ↑, Actinobacteria ↑, Verrucomicrobia ↓ |  | Higher BMI | USA | [96] |
Adults (117 bipolar disorder patients: 49 treated with SGA, 68 non-treated) | 46 | 26 | Clozapine, olanzapine, risperidone, quetiapine, asenapine, ziprasidone, lurasidone, aripiprazole, paliperidone, iloperidone | Akkermansia↓ in non-obese treated vs. untreated patients | Diversity↓ | Higher BMI | USA | [97] |
Age not defined (41 patients with a first episode of schizophrenia and normal body weight) | 23.1 | 56% | Risperidone | Bifidobacterium spp. ↑ |  | Higher BMI, weight gain | China | [56] |